![David Simpson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
David Simpson currently works as a Director at Biosimilars Canada.
Aktive Positionen von David Simpson
Unternehmen | Position | Beginn |
---|---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Commercial Services |